



International Association of

BRIDGE, STRUCTURAL, ORNAMENTAL AND REINFORCING IRON WORKERS

1750 NEW YORK AVE., N.W., SUITE 400, WASHINGTON, D.C. 20006

Affiliated with AFL-CIO

ERIC M. DEAN
GENERAL PRESIDENT
202-383-4810



April 25, 2018

The Honorable Kevin Brady
United States House of Representatives
Washington, D.C. 20215

Dear Mr. Chairman:

The Pharmaceutical Industry Labor-Management Association (PILMA), a coalition of labor organizations and companies in the biopharmaceutical industry, is committed to the dual goals of fostering innovation of life-saving medicines and creating high-quality union construction jobs.

The biopharmaceutical sector support more than 4.7 million American jobs, including members of the building and construction trades unions. It is one of the few manufacturing industries that still maintains a significant employment footprint domestically. In order to devote time and resources to the long-term development of new treatments and cures through research and development, it is essential that strong protections of intellectual property are in place and enforced.

PILMA has a longstanding position supporting intellectual property protections in the U.S. and throughout the world. As PILMA has previously stated, we support intellectual property rights to be part of international rules and regulations that drive U.S. economic growth, job opportunities, and exports.

As your Committees and the Administration looks to use U.S. and international laws to enforce bilateral and multilateral agreements, standards and regulations with countries around the world, we expect high policy and legal standards to be set and enforced. This includes 12 years of data protection for biologics, which is already U.S. law, to be a standard the Administration seeks to apply and enforce with other countries.

Innovation within the biopharmaceutical sector leads to new discoveries that save lives and help this important U.S. industry remain competitive globally. It is essential for the health of all Americans and those around the world and the U.S. jobs the industry provides that this sector is protected with predictable and strong IP protections.

With best wishes and kind personal regards, I am

Very truly yours,

GENERAL PRESIDENT

ED/jh



International Association of

BRIDGE, STRUCTURAL, ORNAMENTAL AND REINFORCING IRON WORKERS

1750 NEW YORK AVE., N.W., SUITE 400, WASHINGTON, D.C. 20006

Affiliated with AFL-CIO

ERIC M. DEAN
GENERAL PRESIDENT
202-383-4810



April 25, 2018

The Honorable Richard Neal
United States House of Representatives
Washington, D.C. 20215

Dear Mr. Neal:

The Pharmaceutical Industry Labor-Management Association (PILMA), a coalition of labor organizations and companies in the biopharmaceutical industry, is committed to the dual goals of fostering innovation of life-saving medicines and creating high-quality union construction jobs.

The biopharmaceutical sector support more than 4.7 million American jobs, including members of the building and construction trades unions. It is one of the few manufacturing industries that still maintains a significant employment footprint domestically. In order to devote time and resources to the long-term development of new treatments and cures through research and development, it is essential that strong protections of intellectual property are in place and enforced.

PILMA has a longstanding position supporting intellectual property protections in the U.S. and throughout the world. As PILMA has previously stated, we support intellectual property rights to be part of international rules and regulations that drive U.S. economic growth, job opportunities, and exports.

As your Committees and the Administration looks to use U.S. and international laws to enforce bilateral and multilateral agreements, standards and regulations with countries around the world, we expect high policy and legal standards to be set and enforced. This includes 12 years of data protection for biologics, which is already U.S. law, to be a standard the Administration seeks to apply and enforce with other countries.

Innovation within the biopharmaceutical sector leads to new discoveries that save lives and help this important U.S. industry remain competitive globally. It is essential for the health of all Americans and those around the world and the U.S. jobs the industry provides that this sector is protected with predictable and strong IP protections.

With best wishes and kind personal regards, I am

Very truly yours,

GENERAL PRESIDENT

ED/jh



International Association of
BRIDGE, STRUCTURAL, ORNAMENTAL AND REINFORCING IRON WORKERS
1750 NEW YORK AVE., N.W., SUITE 400, WASHINGTON, D.C. 20006

Affiliated with AFL-CIO

ERIC M. DEAN
GENERAL PRESIDENT
202-383-4810



April 25, 2018

The Honorable Orrin Hatch
United States Senate
Washington, D.C. 20510

Dear Mr. Chairman:

The Pharmaceutical Industry Labor-Management Association (PILMA), a coalition of labor organizations and companies in the biopharmaceutical industry, is committed to the dual goals of fostering innovation of life-saving medicines and creating high-quality union construction jobs.

The biopharmaceutical sector support more than 4.7 million American jobs, including members of the building and construction trades unions. It is one of the few manufacturing industries that still maintains a significant employment footprint domestically. In order to devote time and resources to the long-term development of new treatments and cures through research and development, it is essential that strong protections of intellectual property are in place and enforced.

PILMA has a longstanding position supporting intellectual property protections in the U.S. and throughout the world. As PILMA has previously stated, we support intellectual property rights to be part of international rules and regulations that drive U.S. economic growth, job opportunities, and exports.

As your Committees and the Administration looks to use U.S. and international laws to enforce bilateral and multilateral agreements, standards and regulations with countries around the world, we expect high policy and legal standards to be set and enforced. This includes 12 years of data protection for biologics, which is already U.S. law, to be a standard the Administration seeks to apply and enforce with other countries.

Innovation within the biopharmaceutical sector leads to new discoveries that save lives and help this important U.S. industry remain competitive globally. It is essential for the health of all Americans and those around the world and the U.S. jobs the industry provides that this sector is protected with predictable and strong IP protections.

With best wishes and kind personal regards, I am

Very truly yours,

GENERAL PRESIDENT

ED/jh



International Association of

BRIDGE, STRUCTURAL, ORNAMENTAL AND REINFORCING IRON WORKERS

1750 NEW YORK AVE., N.W., SUITE 400, WASHINGTON, D.C. 20006

Affiliated with AFL-CIO

ERIC M. DEAN
GENERAL PRESIDENT

202-383-4810



April 25, 2018

The Honorable Ron Wyden
United States Senate
Washington, D.C. 20510

Dear Senator Wyden:

The Pharmaceutical Industry Labor-Management Association (PILMA), a coalition of labor organizations and companies in the biopharmaceutical industry, is committed to the dual goals of fostering innovation of life-saving medicines and creating high-quality union construction jobs.

The biopharmaceutical sector support more than 4.7 million American jobs, including members of the building and construction trades unions. It is one of the few manufacturing industries that still maintains a significant employment footprint domestically. In order to devote time and resources to the long-term development of new treatments and cures through research and development, it is essential that strong protections of intellectual property are in place and enforced.

PILMA has a longstanding position supporting intellectual property protections in the U.S. and throughout the world. As PILMA has previously stated, we support intellectual property rights to be part of international rules and regulations that drive U.S. economic growth, job opportunities, and exports.

As your Committees and the Administration looks to use U.S. and international laws to enforce bilateral and multilateral agreements, standards and regulations with countries around the world, we expect high policy and legal standards to be set and enforced. This includes 12 years of data protection for biologics, which is already U.S. law, to be a standard the Administration seeks to apply and enforce with other countries.

Innovation within the biopharmaceutical sector leads to new discoveries that save lives and help this important U.S. industry remain competitive globally. It is essential for the health of all Americans and those around the world and the U.S. jobs the industry provides that this sector is protected with predictable and strong IP protections.

With best wishes and kind personal regards, I am

Very truly yours,

GENERAL PRESIDENT

ED/jh